Cancer Research and Treatment10.4143/crt.2005.37.1.24200537124High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up ResultHee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Hye Jin Kang, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh,
Cancer Research and Treatment10.4143/crt.2005.37.3.1372005373137High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with 10 or more Positive Lymph Nodes: a 5-Year follow-Up ResultsHee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh,
Medical Oncology10.1007/bf027821932000174287-292ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancerAP Jillella, GW Britt, MS Litaker, AM Kallab, K Harkness, GD Garner,,
Journal of Hematotherapy & Stem Cell Research10.1089/152581699320117199984357-363CD34+ Cell Dose Requirements for Rapid Engraftment in a Sequential High-Dose Chemotherapy Regimen of Paclitaxel, Melphalan, and Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) with PBPC Support in Metastatic Breast CancerKyriakos P. Papadopoulos, Janet Ayello, Robert F. Reiss, Andrea Troxel, Elizabeth Kaufman, Linda T. Vahdat, Karen H. Antman, Charles S. Hesdorffer
European Journal of Cancer10.1016/0959-8049(93)91059-t199329S83High dose chemotherapy (HDCT) with mitoxantrone, cyclophosphamide, vinblastine or carboplatin with bone marrow support in metastatic breast cancer (MBC): Role of autologous peripheral blood stem cell transplantation (PBSCT) and cytokinesJ.M. Nabholtz, S. Gluck,
Cancer Chemotherapy and Pharmacology10.1007/s00280005085619994318-12Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-upYoshinori Ito, Taketo Mukaiyama, Makoto Ogawa, Nobuyuki Mizunuma, Shunji Takahashi, Keisuke Aiba, Noboru Horikoshi,,
Journal of Cancer Research and Clinical Oncology10.1007/s00432-003-0449-320031296361-366Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancerHerbert G. Sayer, Kristina Schilling, Tobias Vogt, Kerstin Blumenstengel, Miriam Charbel Issa, Lars-Olof M�gge, Christoph Kasper, Roland Kath, Klaus H�ffken,,
Bone Marrow Transplantation10.1038/sj.bmt.17008821997204273-281Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftmentTR Klumpp, SL Goldberg, AJ Magdalinski, KF Mangan,,
Cancer10.1002/cncr.307682017123142781-2782High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remissionRevathi Rajagopal, Gordon C. P. Miles, Rishi S. Kotecha,
Bone Marrow Transplantation10.1038/sj.bmt.1702091200025119-24High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II studyHC Toh, SL McAfee, R Sackstein, P Multani, BF Cox, R Garcia-Carbonero, C Colby, TR Spitzer,,